

## Original Article

# *The Results of the Endovascular Management of Femoropopliteal Arterial Occlusive Disease: A Prospective Study on 65 Consecutive Patients*

Majid Moini<sup>1</sup>, MD; Mohammad Reza Zafarghandi<sup>1</sup>, MD; Javad Salimi<sup>1</sup>, MD; Sina Zarrintan<sup>2</sup>, MD; Peyman Bakhshayi<sup>3</sup>, MD; Mohammad Hassani<sup>3\*</sup>, MD

### ABSTRACT

**Background:** We report the angioplasty results of patients suffering from chronic lower extremity ischemia with the involvement of femoropopliteal arteries.

**Methods:** Sixty-five patients were studied. All patients with lower extremity chronic ischemia resulting from femoropopliteal arterial lesions at Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran, from September 22, 2013, through March 21, 2015, were included in the study. The success of angioplasty and stenting was defined as the diminishing of the stenosis to less than 30%. A follow-up Doppler ultrasound was conducted to evaluate restenosis and reocclusion. Additionally, healing of ulcers and recovery of claudication were assessed at follow-up visits.

**Results:** The mean age of the study participants was 64.5±9.7 years. Forty-four patients (67.7%) were male, and 21 patients (32.3%) were female. In follow-up Doppler ultrasounds, 7 patients (10.8%) had stenosis, while 9 patients (13.8%) had occlusion, and 49 patients (75.4%) had a normal patent arterial flow. On follow-up, 53 patients (81.5%) did not report claudication. The success rate of the procedures was 98.46%. The presence of preprocedural tissue gangrene was a potential predictor of restenosis and reocclusion ( $P<0.05$ ).

**Conclusions:** It seems that endovascular management is a feasible and effective technique in lower extremity arterial ischemia due to lesions in femoropopliteal arteries, even in subtypes TASC C and D. (*Iranian Heart Journal 2021; 22(4): 34-44*)

**KEYWORDS:** Femoropopliteal, Angioplasty, Chronic limb ischemia

<sup>1</sup> Department of Vascular and Endovascular Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran.

<sup>2</sup> Department of Surgery, Shohada-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.

<sup>3</sup> Department of Vascular & Endovascular Surgery, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.

\* **Corresponding Author:** Mohammad Hassani, MD; Department of Vascular & Endovascular Surgery, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.

**Email:** drmhassani57@sbmu.ac.ir

**Tel:** +982123031111

**Received:** May 6, 2020

**Accepted:** August 18, 2020

Endovascular therapy is one of the accepted interventions for the treatment of chronic limb ischemia resulting from aortoiliac and femoropopliteal arterial involvements.<sup>1,2</sup> It has been reported

that angioplasty and stenting are more successful in the Trans-Atlantic Inter-Society Consensus on the management of peripheral arterial disease (TASC) types A and B.<sup>3,4</sup> However, a number of reports suggest the

potential benefits of endovascular therapy in all the classes of TASC.<sup>5,6</sup> Thus, endovascular therapy is an effective modality to manage chronic arterial ischemia in the lower extremities. It has been reported that endovascular interventions for TASC B and C femoropopliteal lesions are associated with restenosis or reocclusion rates comparable with those of open bypass surgery.<sup>7</sup> Moreover, endovascular or hybrid approaches have been successfully used for the treatment of the TASC C and D lesions of iliac arteries.<sup>8</sup> Angioplasty has also been used in the TASC lesions of A to D of femoropopliteal involvement in patients with vascular risk factors. It has been reported that diabetes, no stent use, chronic total occlusion, and poor below-the-knee runoff are the potential predictors of restenosis.<sup>9</sup> Herein, we report the angioplasty results of patients with femoropopliteal occlusive disease. The patients were prospectively followed up, and their clinical and sonographic outcomes are presented. Patients with TASC classifications of A to D were included in this study, and endovascular therapy was applied in all the patients. The outcomes are from the Department of Vascular and Endovascular Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. Sina Hospital is a high-volume vascular surgery center in Tehran, Iran, and the report is of potential use and clinical interest.

## METHODS

### Study Sample

We studied the results of angioplasty with or without stenting in patients with femoropopliteal occlusive disease prospectively. Sixty-five prospective patients were studied. All patients with lower extremity arterial chronic ischemia at the Department of Vascular and Endovascular Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran, from September 22, 2013, through March 21, 2015,

were assessed for eligibility to enter the study. The diagnosis of chronic arterial ischemia in lower extremities was made by clinical evaluation and color Doppler studies with or without computed tomography (CT) angiography or digital subtraction angiography (DSA). The classification of arterial ischemia was done based on TASC. The indications for endovascular intervention were intermittent claudication with an impact on the quality of life, rest pain, and tissue loss.

### Inclusion and Exclusion Criteria

The inclusion criteria were composed of normal serum creatinine clearance levels, having patent lumens at the common femoral artery and the proximal superficial femoral artery, and femoropopliteal involvement. The exclusion criteria consisted of chronic kidney disease, elevated serum creatinine levels, history of previous endovascular interventions, history of bypass surgery for chronic lower extremity arterial disease, aortoiliac involvement, and history of previous below-the-knee or above-the-knee amputations. Eighty patients met the inclusion and exclusion criteria of the study. Nonetheless, 10 patients refused to give consent to endovascular treatment. Out of the 70 patients, 5 patients were missed in the follow-up. Finally, 65 patients were followed up and were analyzed for the study purpose (Fig. 1).

### Variables


Background variables were recorded for the patients. These included age, sex, cigarette smoking, hypertension, diabetes mellitus, hyperlipidemia, heart failure, dialysis, and past drug history.

In addition, a complete history was taken, and a physical examination was conducted. The patients were evaluated for claudication, rest pain, tissue gangrene, and ulcers. Minor and major tissue losses were assessed and recorded. The patients had femoropopliteal involvement. The TASC classification was

done. The presence of preprocedural stenosis or occlusion was also recorded. Admission days and follow-up duration were also recorded. The success of angioplasty and stenting was defined as the diminishing of the stenosis to less than 30%. A follow-up Doppler ultrasound was conducted to evaluate restenosis and reocclusion. In addition, healing of ulcers

and recovery of claudication were assessed at follow-up visits.

Hypercholesterolemia was defined as a cholesterol level of more than 200 mg/dL. Hypertension was defined as minimum systolic and diastolic blood pressures 140/90 mm Hg. Chronic kidney disease was considered to be creatinine values greater than 1.5 mg/dL.



**Figure 1.** The flowchart of the study patients is presented herein.

### Endovascular Procedure

All the patients had common femoral or superficial femoral artery stump to introduce angiography sheaths. A loading dose of 300 mg of clopidogrel was administered to the patients prior to angiography and angioplasty. The sheaths were inserted through ipsilateral common or superficial femoral arteries in antegrade fashion to have access to femoropopliteal arteries. The sheaths were placed through the contralateral common femoral artery in a retrograde fashion when a more proximal site of the femoral artery was necessary. Brachial artery access was also used in some cases. The size of the sheaths was 6 to 7 French (F). After sheath introduction, 80 international units per kilogram of body weight of unfractionated heparin was administered.

Standard and hydrophilic guidewires with a diameter of 0.014, 0.018, and 0.035 inches were used. Additionally, 4F and 5F vertebral and JR and MPA1 catheters were used to reach the stenosis or occlusion. After the lesion was crossed, balloon angioplasty was conducted by optimal nominal pressures. If more than 30% stenosis or flow-limiting intimal flap was present after angioplasty or in the long length of the lesion, the stenting of the angioplasty site was conducted.

### Follow-up

All the patients received oral aspirin (80 mg daily), clopidogrel (75 mg daily), and atorvastatin (40 mg daily) for 1 month. Then, aspirin, atorvastatin, and cilostazol (or pentoxifylline) were continued based on indications. All the patients were followed up after 2 to 3 weeks. Then, the patients were followed up every 2 to 3 months, and then every 6 months. Color Doppler ultrasound was conducted 6 months and 1 year after angioplasty. Stenosis less than 50% was considered to be patent. In the cases of restenosis and reocclusion, the

patients were evaluated for signs and symptoms, and repeat angiography and angioplasty were conducted in select cases. All the follow-up visits were conducted by the same vascular surgeon. The Doppler ultrasound studies were also done by a single radiologist, who was an expert in arterial sonography. The endovascular interventions were conducted by the vascular surgeons of Sina Hospital, the Department of Vascular and Endovascular Surgery, Tehran University of Medical Sciences, Tehran, Iran.

### Statistical Analysis

The statistical analyses were conducted using the SPSS 21.0 software. Variables were described as the mean  $\pm$  the standard variation (SD) and frequencies (%). For quantitative variables, the Student *t* test and the one-way ANOVA test for normally distributed data and the Mann–Whitney *U* test for non-normally distributed data were utilized. The associations between qualitative variables were studied using the  $\chi^2$  test or the Fisher exact test. The association between restenosis or reocclusion follow-up color Doppler and background variables was assessed via multivariate analysis using a logistic regression test. The assessment of the patterns of restenosis or reocclusion during the follow-up times regarding the TASC classification was done using the Kaplan–Meier survival analysis. A *P*-value of less than 0.05 was considered statistically significant. Informed consent was obtained from all the study patients.

### Informed Consent

The protocol of the present study was approved by the Research Deputyship of the Faculty of Medicine and the Research Vice-Chancellorship of Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.REC.1395.2763). All consent

forms were obtained by vascular surgery fellows and attending physicians.

## RESULTS

The data of 65 patients were analyzed during the study period. The mean age of the study participants was  $64.5 \pm 9.7$  years. Forty-four patients (67.7%) were male, and 21 patients (32.3%) were female. Twenty-six patients (40.0%) were smokers. The mean cigarette smoking amount was  $37.2 \pm 16.4$  pack-years among the smokers. Table 1 illustrates past disease and drug histories among the study participants. In 1 patient (1.5%), the stenotic lesion was bilateral. The lesions were treated in 33 patients (50.8%) on the right side and 31 patients (47.7%) on the left side.

**Table 1.** Past disease and drug histories among the study participants

Past Medical History	
Disease	
Hypertension	25 (38.5%)
Diabetes mellitus	44 (67.7%)
Hyperlipidemia	6 (9.2%)
Heart failure	9 (13.8%)
Heart disease	5 (7.7%)
Past Drug History	
Drug	
Aspirin	39 (60.0%)
Warfarin	5 (7.7%)
$\beta$ -blocker	10 (15.4%)
Clopidogrel	12 (18.5%)
Statins	25 (38.5%)

The clinical presentations of the study patients prior to endovascular intervention were recorded. Claudication, rest pain, gangrene, and foot ulcers were present in 17 (26.2%), 11 (16.9%), 17 (26.2%), and 20 (30.8%) patients respectively. In addition, the TASC classification of the study patients was as follows: TASC A, 28 patients (43.1%); TASC B, 10 patients (15.4%); TASC C, 11

patients (16.9%); and TASC D, 16 patients (24.6%). The patients were followed up for 24 months. The mean follow-up period was  $13.8 \pm 5.9$  months. The mean preprocedural stenosis rate was  $83.6\% \pm 6.2\%$ , and the mean postprocedural stenosis rate was  $10.9\% \pm 4.7\%$  ( $P=0.000$ ; the paired-sample *t* test). A single procedure was done in 32 patients (49.2%), and multiple procedures were done in 33 patients (50.8%). Fifteen angioplasty procedures were performed without stenting (23.1%). Angioplasty and stenting were done in 54 procedures (83.1%). Overall, 55 stents were used.

Table 2 shows the numbers of angioplasty and stenting in the study patients together with the diameter and length of the stents used in the study patients. The mean admission duration was  $9.6 \pm 8.4$  days, with a minimum and a maximum of 2 and 46 days, respectively. Two main reasons for the prolonged admission were long waiting lists of angioplasty and repeated debridement of the infected and necrotic tissues of the lower extremities after angioplasty.

Table 3 illustrates the clinical and ultrasound findings of the study patients at follow-up visits. Moreover, Table 4 tabulates the association between background pre-interventional variables and follow-up Doppler ultrasound results. These associations were analyzed twice by univariate and multivariate analyses. As is shown in Table 4, only the presence of preprocedural tissue gangrene was a potential predictor of restenosis and reocclusion ( $P<0.05$ ). However, hypertension was a predictive factor ( $P<0.05$ ). The association between restenosis and reocclusion and the preprocedural TASC classification during the follow-up time was analyzed by Kaplan–Meier survival analysis (Fig. 2).

**Table 2.** Numbers of angioplasty and stenting in the study patients together with the diameter and length of the stents used

Variables	Frequency	Number of Stents	Diameter	Length
Single procedure	32 (49.2%)	First stent	6.85±7.38	102.11±46.20
Multiple procedures	33 (50.8%)	Second stent	6.09±0.53	85.00±45.33
Number of stents used	1.15±0.92	Third stent	6.40±0.55	84.46±36.29
Angioplasty alone	15 (23.1%)	Fourth stent	6.00±0.00	150.00±0.00
Angioplasty and stenting	54 (83.1%)			
Self-expandable stents	52 (80.0%)			
Balloon-expandable stents	1 (1.5%)			


**Table 3.** Clinical and ultrasound findings of the study patients at follow-up visits

Variables	Frequency
<i>Ulcers</i>	36 patients
Complete healing of the ulcer	34 patients (94.4%)
Incomplete healing of the ulcer (at least 50%)	0 patients (0.0%)
Ulcers without healing	2 patients (5.6%)
<i>Claudication</i>	43 patients
Recovery of claudication	31 patients (72.1%)
Persistence of claudication	12 patients (27.9%)
<i>Doppler ultrasound</i>	65 patients
Without stenosis or occlusion	49 patients (75.4%)
Stenosis	6 patients (9.2%)
Occlusion	10 patients (15.4%)

**Table 4.** Association between background pre-interventional variables and follow-up Doppler ultrasound results

Variables	Doppler Ultrasound Results			P-value*	P-value**
	Open 49 patients	Stenosis 7 patients	Occlusion 9 patients		
Smoking					
Hypertension	16 patients (32.7%)	4 patients (57.1%)	6 patients (66.7%)	0.099	0.067
Diabetes mellitus	23 patients (46.9%)	0 patients	2 patients (22.2%)	0.032	0.016
Hyperlipidemia	35 patients (71.4%)	4 patients (57.1%)	5 patients (55.6%)	0.529	0.559
Heart failure	5 patients (10.2%)	0 patient	1 patient (11.1%)	0.669	0.492
Heart disease	7 patients (14.3%)	0 patient	2 patients (22.2%)	0.436	0.556
Claudication	3 patients (6.1%)	1 patient (14.3%)	1 patient (11.1%)	0.688	0.180
Gangrene	14 patients (28.6%)	3 patients (42.9%)	2 patients (22.2%)	0.653	0.196
Chronic total occlusion***	10 patients (20.4%)	2 patients (28.6%)	5 patients (55.6%)	0.278	0.030
Stenosis***	31 patients (63.3%)	5 patients (71.4%)	8 patients (88.9%)	0.311	0.178
	83.82±6.50%	83.33±5.77%	80.00±0.00%	0.845	-





**Figure 2.** The image depicts the Kaplan-Meier analysis for the illustration of the patterns of restenosis or reocclusion in the follow-up period based on the TASC classification of the patients.

TASC, Trans-Atlantic Inter-Society Consensus on the management of peripheral arterial disease

## DISCUSSION

The patients were followed up for  $13.8 \pm 5.9$  months. The preprocedural stenosis and postprocedural stenosis rates were  $83.6\% \pm 6.2\%$  and  $10.9\% \pm 4.7\%$ , respectively ( $P < 0.05$ ). Healing of ulcers was seen in 94.4% of the patients. The recovery of claudication was seen in 72.1% of the study population. Follow-up Doppler ultrasound revealed open vasculature in 75.4% of the study participants. Our multivariate analysis showed that preprocedural tissue gangrene was a potent predictor of restenosis or reocclusion following angioplasty for lower extremity chronic arterial ischemia involving the femoropopliteal arterial

vasculature ( $P < 0.05$ ). Hypertension was more common in patients with open vasculature than in patients with restenosis or reocclusion ( $P < 0.05$ ). Nonetheless, it could have been due to selection bias, or it might have resulted from the effects of hypertension on maintaining patency following angioplasty and stenting. In a study by Yin et al,<sup>10</sup> the endovascular treatment of the TASC C and D lesions of femoropopliteal arteries had a high technical success rate and a favorable patency rate. Giles et al<sup>11</sup> reported that infrainguinal angioplasty was a potential treatment for patients with chronic lower extremity ischemia with TASC A, B, and C lesions. Nevertheless, restenosis, re-intervention, or

amputation necessitates careful follow-up. Ratnam et al<sup>1</sup> also reported good technical results and low complication rates in lower limb endovascular interventions, including lesions of aortoiliac, femoropopliteal, and infrapopliteal regions. Favorable outcomes were obtained in 4 groups of TASC A, B, C, and D. We also performed angioplasty in all TASC classification groups, and the results were as good as those reported by other studies. Our study revealed that tissue gangrene was a potent predictor of restenosis or reocclusion in follow-up Doppler studies. Still, complete total occlusion, hyperlipidemia, diabetes, and claudication were not related to sonographic outcomes. Iida et al<sup>9</sup> reported diabetes, no stent use, chronic total occlusion, and poor below-the-knee runoff as potent predictors of poor outcomes after femoropopliteal angioplasty in TASC A to C lesions. Some other studies have also reported the successful use of angioplasty and stenting in femoropopliteal arterial lesions.<sup>12-14</sup>

Symptomatic common and external iliac artery stenosis and occlusion are potential indications for angioplasty and stenting. Park et al<sup>15</sup> reported successful results of iliac artery stenting in a retrospective analysis of 218 patients. They concluded that the TASC classification did not have an impact on outcomes. Their technical success rate was 99%. Leville et al<sup>16</sup> also reported successful endovascular management of iliac artery occlusions in TASC C and D lesions. Their results were comparable with those of open reconstructions. It is suggested that patients with TASC types C and D iliac lesions, a stenotic ipsilateral superficial femoral artery, ulcers or gangrene, smoking history, and chronic renal failure with hemodialysis be followed carefully after endovascular iliac artery intervention.<sup>2</sup> Our study also indicated that gangrene was a potent predictor of angioplasty failure.

Schönefeld et al<sup>17</sup> reported the successful use of endovascular first-line treatment in femoropopliteal arterial lesions even in long segment cases. They used nitinol stents with acceptable long-term patency rates. However, the superiority of bypass surgery over angioplasty has been reported in some studies. In addition, the recurrence of symptoms in superficial femoral artery occlusive disease has been related to TASC D lesions and endovascular therapy. Postoperative statin use has also been a protective factor.<sup>18</sup> We administered aspirin and statin postoperatively for all our patients. A report from Darling et al<sup>19</sup> showed higher wound healing, higher freedom from restenosis, improved patency rates, fewer re-interventions, and higher survival by open surgery than with endovascular interventions in patients with lower extremity chronic limb-threatening ischemia.

Be that as it may, although bypass surgery is feasible and effective, endovascular therapy is also a good option because of its lower complication rate and favorable patency rate among patients in poor condition for bypass.<sup>20</sup> Malas et al<sup>21</sup> compared the results of percutaneous transluminal angioplasty with or without stenting of the superficial femoral artery or femoral-popliteal bypass after the failure of medical management. They reported higher re-intervention rates for femoral-popliteal bypass than with angioplasty and stenting. Nevertheless, this could have been due to selection bias because more severe diseases underwent surgical bypass. The endovascular treatment of the arterial lesions of iliac arteries in TASC groups of A, B, C, and D is technically feasible even in patients with complete total occlusion.<sup>22</sup> Nonetheless, our results revealed that only tissue gangrene was a potent predictor of recurrence and poor sonographic outcomes at follow-up visits. Although nitinol stents have been



accompanied by favorable results,<sup>17</sup> paclitaxel-eluting stents may not prevent in-stent restenosis for TASC C and D lesions.<sup>23</sup> It is worthy of note that stent placement is an effective, safe, and feasible method for the management of long-segment iliac artery complete total occlusions.<sup>24</sup> While based on the mentioned studies, the patency rate in iliac artery angioplasty is good, our study showed that the patency rate in femoropopliteal disease is not as good as that in the iliac artery but is acceptable. Despite the fact that the patency rate in TASC D is low, especially in high-risk patients for surgery, it is deemed an acceptable procedure. In a recent study by Hassani et al<sup>25</sup> in Tehran University of Medical Sciences, Tehran, Iran, a 2-year primary patency rate of aortoiliac occlusive disease was assessed following endovascular treatment. They reported that the endovascular management of different TASC subtypes was associated with a considerable technical success rate and a primary patency rate even in TASC D lesions. These subtypes were previously treated by open bypass surgery. In the present study, the technical, radiological, and clinical success of the endovascular management of femoropopliteal arterial lesions was also confirmed. We also performed endovascular treatment in all TASC groups, even in TASC D patients. Our results are also from the same institution.

The patency of the endovascular procedure was lower in TASC C and D groups during the follow-up. The outcomes were also suboptimal when compared with the results of the previous study by Hassani et al<sup>25</sup> in patients with aortoiliac involvement. The weakness of this study was the low number of patients. A more comprehensive review requires further research on more patients.

In conclusion, endovascular management is a feasible and effective technique in lower

extremity arterial ischemia resulting from lesions in femoropopliteal arteries. Although a number of reports are in favor of open bypass surgery, patient selection should consider all risk factors. Either open surgery or endovascular therapy should be selected based on precise indications. We revealed that tissue gangrene and complete total occlusion were potent predictors of recurrence and poor outcomes. In addition, TASC lesions C and D were related to poor sonographic outcomes during the follow-up period. Further studies with precise sample sizes and subgroup classifications are necessary to reach firm conclusions.

### Acknowledgments

The authors acknowledge Dr Annis Shahnaee for her kind support during the preparation of this article. The authors also thank Dr Mohammad Zakaria Pezeshki from the Department of Community and Family Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, for his kind assistance in data analysis.

### Conflict of Interest

The authors do not have any conflicts of interest. The selection of endovascular equipment was based on procedure indications and was not limited to any specific brands.

### Authors' Contributions

MM, MRZ, JS, and MH designed the study. MH collected the data, which SZ and PB analyzed. SZ drafted the manuscript. MM, MRZ, JS, and MH critically reviewed the manuscript. All the authors read and accepted the final version of the manuscript.

### Financial Support

The study was supported by the Research Center of Surgery at Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.

## Ethical Statement

The protocol of this study was approved by the Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.REC.1395.2763).

## REFERENCES

1. Ratnam L, Raza SA, Horton A, Taylor J, Markose G, Munneke G, Morgan R, Belli AM. Outcome of aortoiliac, femoropopliteal and infrapopliteal endovascular interventions in lesions categorized by TASC classification. *Clin Radiol*. 2012 Oct; 67(10):949-54. doi:10.1016/j.crad.2011.12.011.
2. Kudo T, Chandra FA, Ahn SS. Long-term outcomes and predictors of iliac angioplasty with selective stenting. *J Vasc Surg*. 2005 Sep; 42(3):466-75.
3. Powell RJ, Rzucidlo EM. Aortoiliac Disease: Endovascular Treatment. In: Sidawy AN, Perler BA (eds). *Rutherford's Vascular Surgery and Endovascular Therapy*. 2019; Elsevier, Philadelphia, PA, pp. 1423-1437.
4. Popplewell MA, Bradbury AW. Infringuinal Disease: Endovascular Therapy. In: Sidawy AN, Perler BA (eds). *Rutherford's Vascular Surgery and Endovascular Therapy*. 2019; Elsevier, Philadelphia, PA, pp. 1463-1481.
5. Han DK, Shah TR, Ellozy SH, Vouyouka AG, Marin ML, Faries PL. The success of endovascular therapy for all TransAtlantic Society Consensus graded femoropopliteal lesions. *Ann Vasc Surg*. 2011 Jan; 25(1):15-24. doi:10.1016/j.avsg.2010.06.003.
6. Tewksbury R, Pearch B, Redmond K, Harper J, Klein K, Quinn J. Outcomes of infrapopliteal endoluminal intervention for transatlantic intersociety consensus C and D lesions in patients with critical limb ischaemia. *ANZ J Surg*. 2014 Nov; 84(11):866-70. doi:10.1111/ans.12460.
7. Baril DT, Marone LK, Kim J, Go MR, Chaer RA, Rhee RY. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions. *J Vasc Surg*. 2008 Sep; 48(3):627-33. doi:10.1016/j.jvs.2008.04.059.
8. Taurino M, Persiani F, Fantozzi C, Ficarelli R, Rizzo L, Stella N. Trans-Atlantic Inter-Society Consensus II C and D iliac lesions can be treated by endovascular and hybrid approach: a singlecenter experience. *Vasc Endovascular Surg*. 2014 Feb; 48(2):123-8. doi:10.1177/1538574413512381.
9. Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Suematsu N, Yamaoka T, Nanto S, Uematsu M. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery. *JACC Cardiovasc Interv*. 2014 Jul; 7(7):792-8. doi:10.1016/j.jcin.2014.01.168.
10. Yin MY, Jiang ME, Huang XT, Lu M, Lu XW, Huang Y, Li WM. Endovascular interventions for TransAtlantic InterSociety Consensus II C and D femoropopliteal lesions. *Chin Med J (Engl)*. 2013 Feb; 126(3):415-20.
11. Giles KA, Pomposelli FB, Spence TL, Hamdan AD, Blattman SB, Panossian H, Schermerhorn ML. Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. *J Vasc Surg*. 2008 Jul; 48(1):128-36. doi:10.1016/j.jvs.2008.02.027.
12. Dearing DD, Patel KR, Compoginis JM, Kamel MA, Weaver FA, Katz SG. Primary stenting of the superficial femoral and popliteal artery. *J Vasc Surg*. 2009 Sep; 50(3):542-7. doi:10.1016/j.jvs.2009.04.019.
13. Bonvini RF, Rastan A, Sixt S, Beschorner U, Noory E, Schwarz T, Roffi M, Dorsaz PA, Schwarzwälder U, Bürgelin K, Macharzina R, Zeller T. Angioplasty and provisional stent treatment of common femoral artery lesions. *J Vasc Interv Radiol*. 2013 Feb; 24(2):175-83. doi:10.1016/j.jvir.2012.10.020.

14. Lee JJ, Katz SG. The number of patent tibial vessels does not influence primary patency after nitinol stenting of the femoral and popliteal arteries. *J Vasc Surg.* 2012 Apr; 55(4):994-1000; discussion 1000. doi:10.1016/j.jvs.2011.10.106.
15. Park KB, Do YS, Kim DI, Kim DK, Kim YW, Shin SW, Cho SK, Choo SW, Choe YH, Choo IW. The TransAtlantic InterSociety Consensus (TASC) classification system in iliac arterial stent placement: long-term patency and clinical limitations. *J Vasc Interv Radiol.* 2007 Feb; 18(2):193-201.
16. Leville CD, Kashyap VS, Clair DG, Bena JF, Lyden SP, Greenberg RK, O'Hara PJ, Sarac TP, Ouriel K. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. *J Vasc Surg.* 2006 Jan; 43(1):32-9.
17. Schönefeld E, Torsello G, Osada N, Herten M, Bisdas T, Donas KP. Long-term outcome of femoropopliteal stenting. Results of a prospective study. *J Cardiovasc Surg (Torino).* 2013 Oct; 54(5):617-23.
18. Siracuse JJ, Giles KA, Pomposelli FB, Hamdan AD, Wyers MC, Chaikof EL, Nedeau AE, Schermerhorn ML. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. *J Vasc Surg.* 2012 Apr; 55(4):1001-7. doi:10.1016/j.jvs.2011.10.128.
19. Darling JD, McCallum JC, Soden PA, Korepta L, Guzman RJ, Wyers MC, Hamdan AD, Schermerhorn ML. Results for primary bypass versus primary angioplasty/stent for lower extremity chronic limb-threatening ischemia. *J Vasc Surg.* 2017 Aug; 66(2):466-475. doi:10.1016/j.jvs.2017.01.024.
20. Aihara H, Soga Y, Mii S, Okazaki J, Yamaoka T, Kamoi D, Shintani Y, Ishikawa T; RECANALISE Registry Investigators. Comparison of long-term outcome after endovascular therapy versus bypass surgery in claudication patients with Trans-Atlantic Inter-Society Consensus-II C and D femoropopliteal disease. *Circ J.* 2014; 78(2):457-64.
21. Malas MB, Enwerem N, Qazi U, Brown B, Schneider EB, Reifsnnyder T, Freischlag JA, Perler BA. Comparison of surgical bypass with angioplasty and stenting of superficial femoral artery disease. *J Vasc Surg.* 2014 Jan; 59(1):129-35. doi:10.1016/j.jvs.2013.05.100.
22. Papakostas JC, Chatzigakis PK, Peroulis M, Avgos S, Kouvelos G, Lazaris A, Matsagkas MI. Endovascular Treatment of Chronic Total Occlusions of the Iliac Arteries: Early and Midterm Results. *Ann Vasc Surg.* 2015 Nov; 29(8):1508-15. doi:10.1016/j.avsg.2015.07.011.
23. Davaine JM, Querat J, Kaladji A, Guyomarch B, Chaillou P, Costargent A, Quillard T, Gouëffic Y. Treatment of TASC C and D Femoropopliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry. *Eur J Vasc Endovasc Surg.* 2015 Nov; 50(5):631-7. doi:10.1016/j.ejvs.2015.07.018.
24. Ye K, Lu X, Yin M, Li W, Huang Y, Huang X, Lu M, Jiang M. Midterm outcomes of stent placement for long-segment iliac artery chronic total occlusions: a retrospective evaluation in a single institution. *J Vasc Interv Radiol.* 2013 Jun; 24(6):859-64. doi:10.1016/j.jvir.2013.02.038.
25. Hassani M, Zafarghandi MR, Taghavi M, Salimi J, Moini M, Sharifi A, Noaparast M, Toubaei MR, Shahbandari M, Naserinia SA, Saadat S, Biniiaz F. Two-Year Primary Patency Rates After Aortoiliac Occlusive Disease Endovascular Treatment, Iran *J Radiol.* 2018; 15(2):e59509. doi:10.5812/iranradiol.59509.